Valneva SE (EPA:VLA)
France · Delayed Price · Currency is EUR 3.946
+0.306 (8.41%)
Aug 12, 2025, 4:45 PM CET
Valneva SE Revenue
Valneva SE had revenue of 49.23M EUR in the quarter ending March 31, 2025, with 50.31% growth. This brings the company's revenue in the last twelve months to 186.06M, up 21.64% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
186.06M
Revenue Growth
+21.64%
P/S Ratio
3.33
Revenue / Employee
260.95K
Employees
713
Market Cap
619.03M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 27.24B |
| Sanofi | 45.74B |
| Sartorius Stedim Biotech | 2.90B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 7.14B |
| Ipsen | 3.76B |
| ABIVAX Société Anonyme | 10.59M |
| Virbac | 1.40B |
Valneva SE News
- 10 hours ago - Valneva reports 1H results; reaffirms FY outlook - Seeking Alpha
- 10 hours ago - Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 5 days ago - FDA lifts pause on Valneva's chikungunya vaccine in elderly - Seeking Alpha
- 5 days ago - Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information - GlobeNewsWire
- 14 days ago - AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate - Business Wire
- 4 weeks ago - Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly - GlobeNewsWire
- 4 weeks ago - Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults - Reuters
- 6 weeks ago - Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus - GlobeNewsWire